Search

AIM: To explore the application effect of capsular tension ring(CTR)in phacoemulsification(Phaco)combined with intraocular lens(IOL)implantation for patients with high myopia, cataract and suspensory ligament relaxation.METHODS: Prospective study. A total of 80 patients(80 eyes)with high myopia, cataract and suspensory ligament relaxation who underwent Phaco combined with IOL implantation in the hospital between April 2020 and August 2021 were enrolled. According to random number table method, they were divided into CTR group(Phaco combined with CTR and IOL implantation)and control group(Phaco combined with IOL implantation), with 40 cases(40 eyes)in each group. The best corrected distance visual acuity(BCDVA), anterior capsule area, total IOL inclination and subjective visual quality before and after surgery were compared between the two groups.RESULTS: At 1, 3 and 6mo after surgery, BCDVA was improved(P

AIM: To investigate the effect of modified Ahmed drainage valve implantation combined conbercept in the treatment of neovascular glaucoma.METHODS: Neovascular glaucoma patients(59 cases, 60 eyes)were separated into experiment group(20 cases, 21 eyes)and control group(39 cases, 39 eyes)in our hospital from 2015 to 2018. Patients in the experiment group received Ahmed drainage valve implantation and intravitreal conbercept injection while patients in the control group were treated with ciliarybody photocoagulation. The visual acuity, intraocular pressure and iris neovessels were observed in 3mo after operation.RESULTS: There was no significantly difference in the preoperative data between the two groups and both of them can decrease intraocular pressure(PPZ=2.74,PCONCLUSION: Modified Ahmed drainage valve implantation combined with intravitreal conbercept injection can effectively decrease the intraocular pressure for a long time and make the iris neovessels vanish.

AIM: To evaluate the efficacy of half-dose verteporfin photodynamic therapy for central serous chorioretinophathy(CSC)in patients aged above 45 years old. METHODS: Thirty-two eyes of 30 patients aged above 45 years old with central serous chorioretinophathy were included, and all the eyes received half-dose verteporfin photodynamic therapy(PDT). Best-corrected visual acuity(BCVA), central macular thickness(CMT)and subretinal fluids absorption(SRF)were measured before and after treatment(1,3 and 6mo).RESULTS: The rate of SRF absorbing completely was 44% at 1mo, 63% at 3mo and 75% at 6mo. The difference in cure rate of the three time points was statistically significant(χ2=6.621, P=0.037). All the patients were divided into two groups according to the duration, patients in Group A were treated less than 6mo, Group B were ≥6mo. The mean LogMAR BCVA in the two groups were respectively 0.6149±0.4117 and 0.8167±0.4370 before treatment and the mean CMT were 409.47±129.422μm and 395.82±153.756μm before treatment. The difference between the two groups in the LogMAR BCVA was not statistically significant(F=0.303, P=0.823), but the time difference within the subjects was statistically significant(F=32.837,PPt=2.024,P=0.063). In Group B, the differences of the LogMAR BCVA at any two time points were all statistically significant(PF=0.064,P=0.978), but the time difference within the subjects was statistically significant(F=26.447,PPPCONCLUSION: Half-dose verteporfin PDT was effective in treating CSC aged above 45 years old, it still could improve BCVA and subretinal fluids absorption.

AIM:To understand the clinic effect of intravitreal anti-vascular endothelial growth factor(VEGF)drugs injection in the treatment of fundus disease in the real-world study(RWS). METHODS: The clinical cases treated with anti-VEGF drugs in our department from September 2012 to June 2015 were enrolled in this study. Retrospective investigation was reviewed to the kinds of diseases, frequency, usage, efficacy, adverse reaction, and the effects on visual acuity, fundus and macular thickness which were treated with intravitreal anti-VEGF drugs injection. RESULTS: In 305 patients(340 eyes)treated with anti-VEGF drugs, 53 patients(60 eyes, 17.6%)were wet age-related macular degeneration(AMD), polypoidal choroidal vasculopathy(PCV)16 cases(18 eyes, 5.3%), diabetic macular edema(DME)120 cases(134 eyes, 39.4%), branch retinal vein occlusion(BRVO)secondary macular edema 61 cases(68 eyes, 20.0%), central retinal vein occlusion(CRVO)secondary macular edema 29 cases(32 eyes, 9.4%), idiopathic choroidal neovascularization(ICNV)16 cases(18 eyes, 5.3%), high myopia with choroid neovascularization 4 cases(4 eyes, 1.2%), neovascular glaucoma 4 cases(4 eyes, 1.2%), retinal angiomatous proliferation(RAP)1 cases(1 eyes, 0.2%)and optic papillary neovascularization 1 cases(1 eyes, 0.2%). The minimum age was 16 years old, and the maximum age 90 years old. There were 247 cases(275 eyes, 80.9%)were treated with intravitreal ranibizumab injection, 58 cases(65 eyes, 19.1%)intravitreal conbercept injection. The time number of all patients accepted anti-VEGF drugs treatment was 465, with an average of 1.7 times per eye. Which, the "3 + PRN" treatment method in 98 patients(109 eyes, 32.1%), "1 + PRN" treatment in 207 patients(231 eyes, 67.9%). 69 cases(77 eyes, 22.6%)were used alone to receive anti-VEGF drugs therapy, 10 cases(11 eyes, 3.2%)combined with intravitreal triamcinolone injection(TA), 35 cases(39 eyes, 11.5%)combined with vitrectomy, 26 cases(29 eyes, 8.5%)combined with photodynamic treatment(PDT), 165 cases(184 eyes, 54.1%)combined with simple laser treatment. After anti-VEGF drug treatment, majority of patients' the best corrected visual acuity(BCVA), fundus and central macular thickness(CMT)were significantly improved, compared with the pre-treatment, the difference is significant(PCONCLUSION: Intravitreal anti-VEGF drugs injection can significantly improve the visual function and ocular fundus for patients with fundus diseases, but there are still some adverse events, which should be attached great importance to medical workers.

AIM:To discuss the diagnosis of Vogt-Koyanagi-Harada syndrome(VKHS)and evaluate the clinical effect of different corticosteroid therapies. METHODS: Forty-five patients(90 eyes)from January 2010 to February 2014 with VKHS were enrolled in this retrospective case study. The patients were divided into two groups. Twenty-five patients(50 eyes)in observation group were treated with methylprednisolone(1.0g)for 3 days. Then the methylprednisolone was reduced to 0.5g per day in the fourth and fifth day. Twenty patients(40 eyes)in control group were treated with dexamethasone(12mg)for 5 days. Then 60mg of prednisone were given to all the 45 patients and reduced according to the patients' inflammatory, taken off 5mg every time. When the dose was reduced to 15～20mg, the treatment was sustained for 6mo at least. Then the dose was reduced again till prednisone was taken off. The total course of treatment was more than 9mo. All patients underwent B type ultrasound scan, optical coherence tomography(OCT)and fundus fluorescein angiography(FFA)before and after treatments. The changes were analyzed. RESULTS: There was no statistical significance on vision between the two groups before treatments. Vision of all patients improved after treatments, and that in observation group(0.44±0.19)were significantly better than that in control group(0.55±0.29)at the fifth day(PP>0.05). Thirty days after treatment, vision of the two groups was almost back to normal. According to OCT, 84 eyes(93%)had macular neuroepithelial detachment or serous macular detachment, and height of detachment was 1009.67±319.40 μm in observation group, 1098.13±283.45μm in control group. Five days after treatments, the height of detachment in observation group was 307.79±71.35μm, significantly lower than control group(434.13±88.67μm)(PP>0.05). And 30 days after treatments, the morphology of fovea was almost back to normal. One month after treatments, the FFA results were almost normal, expect 8 eyes had slightly leakage.CONCLUSION: Large dose of methylprednisolone in early stage can improve the VKH patients' vision and promote the subretinal effusion absorption, which has better clinic effect and less adverse reaction than dexamethasone, is worth spread.

AIM: To investigate the efficiency and security of compound anisodine injection in the treatment of juxtafoveal central serous chorioretinopathy(CSC). METHODS: Sixty patients(60 eyes)who were diagnosed of juxtafoveal CSC were assigned randomly into 2 groups: 32 cases(32 eyes, therapeutic group)were injected subcutaneously compound anisodine injection for 2mL q.d around superficial temporal arteries in the affected eyes; 28 cases(28 eyes, control group)received only traditional oral medication. Both groups received therapy for 2 to 4 courses of treatment. The main observations were the best corrected visual acuity(BCVA), subjective symptom, visual field, average light sensitivity and optical coherent topography(OCT).RESULTS: There was no significant difference between the therapeutic group and the control group before treatment(P>0.05), but all the outcome measures at 1, 3mo in the treatment group were significantly improved as compared with control group(PP>0.05). No severe adverse reaction was noted except mild ones such as temporary dry mouth, dizziness and palpitation in a few cases.CONCLUSION: Compound anisodine injection has remarkable effects in the treatment of juxtafoveal CSC. It can shorten the course, improved the visual function and decreased the recurrence rate of CSC.

AIM: To observe the clinical effect of low power transpupillary thermotherapy(TTT)with retrobulbar injection of triamcinolone acetonide(TA)for central exudative chorioretinopathy(CEC).METHODS: Fourteen eyes with idiopathic choroidal neovascularization were treated with retrobulbar injection of TA and performed by low power TTT after one week. Laser parameters were as follows: spot diameter 0.8-3.0mm, low power 120-360mW, time 60 seconds. By 3 to 12 months of follow-up, visual acuity, ophthalmoscope, fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were used to observe the curative effects.RESULTS: Visual acuity were improved in 5 eyes(36%), remained stable in 8 eyes(57%)and declined in 1 eye(7%)after treatment. The macular hemorrhage and exudation were reduced significantly in 12 eyes. FFA showed that the fluorescein leakage ceased or decreased in 7 eyes, unchanged in 5 eyes, and enlarged in 2 eyes. The macular edema of 12 eyes in OCT was reduced unequally.CONCLUSION: Low power TTT combined with retrobulbar injection of TA shows good therapeutic effect on CEC.